Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review.

van Bruggen, F H; Nijhuis, G B J; Zuidema, S U; Luijendijk, Hendrika

van Bruggen, F H; Nijhuis, G B J; Zuidema, S U; Luijendijk, Hendrika.

Afiliação

van Bruggen FH; University of Groningen, University Medical Center Groningen, Department of General Practice and Elderly Care Medicine , Groningen, The Netherlands.
Nijhuis GBJ; University of Groningen, University Medical Center Groningen, Department of General Practice and Elderly Care Medicine , Groningen, The Netherlands.
Zuidema SU; University of Groningen, University Medical Center Groningen, Department of General Practice and Elderly Care Medicine , Groningen, The Netherlands.
Luijendijk H; University of Groningen, University Medical Center Groningen, Department of General Practice and Elderly Care Medicine , Groningen, The Netherlands.

Expert Rev Clin Pharmacol ; 13(7): 787-796, 2020 Jul.

Article em En | MEDLINE | ID: mdl-32597252

Assuntos

Anticolesterolemiantes/administração & dosagem; Hipercolesterolemia/tratamento farmacológico; Inibidores de PCSK9; Anticolesterolemiantes/efeitos adversos; Anticolesterolemiantes/farmacologia; Doenças Cardiovasculares/prevenção & controle; Humanos; Hipercolesterolemia/complicações; Ensaios Clínicos Controlados Aleatórios como Assunto

Palavras-chave

Adverse events; ClinicalTrials.gov; PCSK9 inhibitors; all-cause mortality; review

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de PCSK9 / Hipercolesterolemia / Anticolesterolemiantes Tipo de estudo: Clinical_trials / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Expert Rev Clin Pharmacol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google